Partner Therapeutics Strengthens Oncology Portfolio With BIZENGRI
LEXINGTON, Mass., May 11, 2026 Partner Therapeutics, Inc. (PTx) announced that the U.S. Food and Drug Administration (FDA) has...
NRG1 Fusion
Advertisement
FDA Approves Bizengri for Rare Cholangiocarcinoma
SILVER SPRING, Maryland, May 8, 2026 The U.S. Food and Drug Administration (FDA) has approved Bizengri (zenocutuzumab-zbco) for the...
Partner Therapeutics Gains FDA Priority Voucher for BIZENGRI®
LEXINGTON, Massachusetts, United States – May 6, 2026 Partner Therapeutics has announced that the U.S. Food and Drug Administration...
Partner Therapeutics Files sBLA for BIZENGRI in CCA
LEXINGTON, MASSACHUSETTS, USA, April 14, 2026 Partner Therapeutics, Inc. has announced the submission of a supplemental Biologics License Application...
Zenocutuzumab Extends Benefit in NRG1+ NSCLC
LEXINGTON, Mass., February 20, 2026 — New findings from a post hoc analysis of the ongoing eNRGy trial reveal...
Advertisements
Zenocutuzumab Gains FDA Orphan Drug Status in CCA
WALTHAM, Mass., Feb. 2026 — Partner Therapeutics announced that zenocutuzumab-zbco, an investigational bispecific antibody therapy, has received U.S. FDA...
Zenocutuzumab-zbco Earns FDA Breakthrough Therapy Status for NRG1+ Cholangiocarcinoma
LEXINGTON, Mass., October 23, 2025– Partner Therapeutics, Inc. (PTx), a fully integrated biotechnology company, announced that the U.S. Food...
Advertisement
